Gastric Peroral Endoscopic Pyloromyotomy Reduces Symptoms, Increases Quality of Life, and Reduces Health Care Use For Patients With Gastroparesis.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
01 2019
Historique:
received: 15 08 2017
revised: 01 04 2018
accepted: 08 04 2018
pubmed: 17 4 2018
medline: 30 1 2020
entrez: 17 4 2018
Statut: ppublish

Résumé

Gastric peroral endoscopic pyloromyotomy (GPOEM) is becoming a promising treatment option for patients with refractory gastroparesis. We aimed to systematically assess the efficacy of GPOEM and its effects on health care use. We performed a retrospective study on 30 patients with refractory gastroparesis who underwent GPOEM from June 2015 through July 2017 at a tertiary center. We compared outcomes with those of 7 patients with refractory gastroparesis who did not undergo the procedure (controls). The primary outcomes were patient-reported reductions in symptoms, based on the gastroparesis cardinal symptom index (GCSI), and increases in 8 aspects of quality of life, based on Short Form 36 (SF-36) scores. Data were collected on the day of the procedure (baseline) and at 1 month, 6 months, 12 months, and 18 months afterward. Secondary outcomes included visits to the emergency department or hospitalization for gastroparesis-related symptoms. GPOEM was technically successful in all patients and significantly reduced GCSI scores in repeated-measure analysis of variance (F In a retrospective study of patients who underwent GPOEM for refractory gastroparesis, we found the procedure significantly improved symptoms, increased quality of life, and reduced health care use related to gastroparesis.

Sections du résumé

BACKGROUND & AIMS
Gastric peroral endoscopic pyloromyotomy (GPOEM) is becoming a promising treatment option for patients with refractory gastroparesis. We aimed to systematically assess the efficacy of GPOEM and its effects on health care use.
METHODS
We performed a retrospective study on 30 patients with refractory gastroparesis who underwent GPOEM from June 2015 through July 2017 at a tertiary center. We compared outcomes with those of 7 patients with refractory gastroparesis who did not undergo the procedure (controls). The primary outcomes were patient-reported reductions in symptoms, based on the gastroparesis cardinal symptom index (GCSI), and increases in 8 aspects of quality of life, based on Short Form 36 (SF-36) scores. Data were collected on the day of the procedure (baseline) and at 1 month, 6 months, 12 months, and 18 months afterward. Secondary outcomes included visits to the emergency department or hospitalization for gastroparesis-related symptoms.
RESULTS
GPOEM was technically successful in all patients and significantly reduced GCSI scores in repeated-measure analysis of variance (F
CONCLUSIONS
In a retrospective study of patients who underwent GPOEM for refractory gastroparesis, we found the procedure significantly improved symptoms, increased quality of life, and reduced health care use related to gastroparesis.

Identifiants

pubmed: 29660525
pii: S1542-3565(18)30372-0
doi: 10.1016/j.cgh.2018.04.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

82-89

Informations de copyright

Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Parit Mekaroonkamol (P)

Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia.

Sunil Dacha (S)

Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia.

Lei Wang (L)

Department of Gastroenterology, Nanjing Drum Tower Hospital, Nanjing, China.

Xiaoyu Li (X)

Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Yueping Jiang (Y)

Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Lianyong Li (L)

Department of Gastroenterology, PLA 306 Hospital, Beijing, China.

Tian Li (T)

Weihai Municipal Hospital, Weihai, China.

Nikrad Shahnavaz (N)

Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia.

Sonali Sakaria (S)

Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia.

Francis E LeVert (FE)

Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia.

Steven Keilin (S)

Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia.

Field Willingham (F)

Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia.

Jennifer Christie (J)

Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia.

Qiang Cai (Q)

Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia. Electronic address: qcai@emory.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH